利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

89 条记录 (耗时 0.052 秒)

    6,11-4-Carbon bridged ketolides
    11.
    发明授权
    6,11-4-Carbon bridged ketolides 失效
    6,11-4-碳桥式酮内酯

    公开(公告)号：US07049417B2

    公开(公告)日：2006-05-23

    申请号：US10841206

    申请日：2004-05-07

    申请人： Yat Sun Or ,  Guoqiang Wang ,  Deqiang Niu ,  Ly Tam Phan

    发明人： Yat Sun Or ,  Guoqiang Wang ,  Deqiang Niu ,  Ly Tam Phan

    IPC分类号： C07H1/00

    CPC分类号： C07H17/08

    摘要： Novel 6,11-4-carbon bridged ketolides, pharmaceutically-acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also described are a method for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically effective amount of a compound of the invention and processes for the preparation of such compounds.

    摘要翻译： 描述了包含治疗有效量的本发明化合物与药学上可接受的载体的新颖的6,11-4-碳桥连酮内酯，药学上可接受的组合物。 还描述了通过向动物施用含有治疗有效量的本发明化合物和制备这些化合物的方法的药物组合物来治疗细菌感染的方法。

    11-O-substituted macrolides and their descladinose derivatives
    12.
    发明授权
    11-O-substituted macrolides and their descladinose derivatives 失效
    11-O-取代的大环内酯类及其衍生物

    公开(公告)号：US06673774B2

    公开(公告)日：2004-01-06

    申请号：US10011322

    申请日：2001-12-03

    申请人： Ly Tam Phan Phan ,  Deqiang Niu ,  Yat Sun Or

    发明人： Ly Tam Phan Phan ,  Deqiang Niu ,  Yat Sun Or

    IPC分类号： A61K3170

    CPC分类号： C07H17/08

    摘要： There are described 11-O-substituted macrolides and their descladinose derivatives and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described is a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds.

    摘要翻译： 描述了11-O-取代的大环内酯及其下拉曲肽衍生物和药学上可接受的组合物，其包含治疗有效量的本发明化合物与药学上可接受的载体的组合。 还描述了一种通过向哺乳动物施用含有治疗有效量的本发明化合物的药物组合物及其制备方法来治疗细菌感染的方法。

    11-O-substituted ketolide derivatives
    13.
    发明授权
    11-O-substituted ketolide derivatives 失效
    11-O-取代的酮内酯衍生物

    公开(公告)号：US06670331B2

    公开(公告)日：2003-12-30

    申请号：US10011642

    申请日：2001-12-04

    申请人： Ly Tam Phan Phan ,  Deqiang Niu ,  Yat Sun Or

    发明人： Ly Tam Phan Phan ,  Deqiang Niu ,  Yat Sun Or

    IPC分类号： A61K3170

    CPC分类号： C07H17/08

    摘要： There are described novel 11-O-substituted ketolide derivatives of clarithromycin analogs and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described is a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds.

    摘要翻译： 描述了克拉霉素类似物的新的11-O-取代的酮内酯衍生物和药学上可接受的组合物，其包含治疗有效量的本发明化合物与药学上可接受的载体的组合。 还描述了一种通过向哺乳动物施用含有治疗有效量的本发明化合物的药物组合物及其制备方法来治疗细菌感染的方法。

    9N-substituted 6-11 bicyclic erythromycin derivatives
    16.
    发明授权
    9N-substituted 6-11 bicyclic erythromycin derivatives 失效
    9N-取代的6-11双环红霉素衍生物

    公开(公告)号：US07265094B2

    公开(公告)日：2007-09-04

    申请号：US11031465

    申请日：2005-01-07

    申请人： Yao-Ling Qiu ,  Deqiang Niu ,  Zhe Wang ,  Ly Tam Phan ,  Yat Sun Or

    发明人： Yao-Ling Qiu ,  Deqiang Niu ,  Zhe Wang ,  Ly Tam Phan ,  Yat Sun Or

    IPC分类号： A61K31/70 ,  C07H17/08

    CPC分类号： C07H17/08

    摘要： The present invention discloses compounds of formula I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

    摘要翻译： 本发明公开了式I，II，III或IV的化合物或其外消旋物，对映异构体，区域异构体，盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

    Quinoxalinyl derivatives
    18.
    发明授权
    Quinoxalinyl derivatives 有权
    喹喔啉衍生物

    公开(公告)号：US08962551B2

    公开(公告)日：2015-02-24

    申请号：US12327538

    申请日：2008-12-03

    申请人： Deqiang Niu ,  Dong Liu ,  Joel D. Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

    发明人： Deqiang Niu ,  Dong Liu ,  Joel D. Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/00 ,  A01N37/18 ,  C07D487/04 ,  A61K38/21 ,  C07K5/078 ,  C07K5/087

    CPC分类号： C07D487/04 ,  A61K38/212 ,  A61K38/215 ,  C07K5/06165 ,  C07K5/0812 ,  A61K2300/00

    摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译： 本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Arylalkoxyl hepatitis C virus protease inhibitors
    19.
    发明授权
    Arylalkoxyl hepatitis C virus protease inhibitors 失效
    芳酰基甲酰丙型肝炎病毒蛋白酶抑制剂

    公开(公告)号：US07687459B2

    公开(公告)日：2010-03-30

    申请号：US11836288

    申请日：2007-08-09

    申请人： Deqiang Niu ,  Yonghua Gai ,  Yat Sun Or ,  Zhe Wang

    发明人： Deqiang Niu ,  Yonghua Gai ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/12 ,  A61K38/06 ,  A61K39/42

    CPC分类号： C07D487/04 ,  A61K38/21 ,  A61K38/212 ,  C07D207/16 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07K5/0804 ,  C07K5/0808 ,  A61K2300/00

    摘要： The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译： 本发明公开了式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
    20.
    发明申请
    AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
    AZA-TRIPEPTIDE HEPATITIS C丝氨酸蛋白酶抑制剂

    公开(公告)号：US20080287449A1

    公开(公告)日：2008-11-20

    申请号：US12108647

    申请日：2008-04-24

    申请人： Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    发明人： Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K31/40 ,  A61P31/12 ,  C07D409/14 ,  C07D207/16 ,  C07D403/12 ,  C07D417/14 ,  C07D401/12 ,  C07D495/04 ,  C07D471/04 ,  A61K31/498 ,  A61K31/519 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4035

    CPC分类号： A61K38/21 ,  C07K5/06165 ,  A61K2300/00

    摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。